Opioid Dependency in Pregnancy and Length of Stay for Neonatal Abstinence Syndrome



      To examine opioid replacement therapy in pregnancy and effect on neonatal outcomes, including length of hospital stay for neonatal abstinence syndrome.


      Retrospective descriptive study.


      Labor and delivery unit and neonatal intensive care unit (NICU), Eastern Maine Medical Center, Bangor, Maine.


      One hundred fifty‐two opioid‐dependent pregnant women on methadone maintenance therapy (MMT) (n = 136) or buprenorphine maintenance therapy (BMT) (n = 16) during pregnancy and their neonates. The neonates were born between January 1, 2005 and December 31, 2007.


      A review of the electronic medical record (EMR) was conducted of all opioid‐dependent women who were maintained on MMT or BMT at the time of admission for labor and delivery and their neonates.


      Maternal methadone dose and concomitant in‐utero exposure to benzodiazepines prolonged the length of hospital stay for neonates. Length of stay was shorter in breastfed neonates than formula‐fed neonates or neonates who received formula and breast milk. Neonates with prenatal exposure to MMT spent more days in the hospital (21 vs. 14 days) for treatment of neonatal abstinence syndrome (NAS) than infants with prenatal exposure to BMT.


      These findings are consistent with previous research on the simultaneous use of methadone and benzodiazepines during pregnancy and provide further direction for the treatment of opioid dependency during pregnancy. Harm reduction strategies for opioid‐dependent pregnant women in substance abuse treatment with MMT may one day include guidance on daily treatment doses and recommendations to avoid the concomitant use of benzodiazepines to lessen NAS. Breastfeeding should be recommended to shorten length of stay. Understanding perinatal and neonatal outcomes of pregnant women on methadone or buprenorphine will help to identify optimal treatment for opioid dependency in pregnancy.


      To read this article in full you will need to make a payment
      AWHONN Member Login
      AWHONN Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Almario C.V.
        • Seligman N.S.
        • Dysart K.C.
        • Berghella V.
        • Baxter J.K.
        Risk factors for preterm birth among opiate–addicted gravid women in a methadone treatment program.
        American Journal of Obstetrics & Gynecology. 2009; 201: 326.e1-326.e6
        • Arlettaz R.
        • Kashiwagi M.
        • Das‐Kundu S.
        • Fauchere J.C.
        • Lang A.
        • Bucher H.U.
        Methadone maintenance program in pregnancy in a Swiss perinatal center (II): Neonatal outcome and social resources.
        Acta Obstetricia et Gynecologica Scandinavica. 2005; 84: 145-150
        • Binder T.
        • Vavrinkova B.
        Prospective randomized comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birth weight of newborns, early postpartum adaptation and course of neonatal abstinence syndrome (NAS) in women followed up in the outpatient department.
        Neuroendocrinology Letters. 2008; 29: 80-86
        • Brown M.
        • Hayes M.
        • LaBrie S.
        Breast feeding is associated with decreased risk and length of treatment for neonatal abstinence syndrome (NAS) in methadone and buprenorphine exposed infants.
        Boston, MA2011
        • Burns L.
        • Mattick R.P.
        • Lim K.
        • Wallace C.
        Methadone in pregnancy: Treatment retention and neonatal outcomes.
        Addiction. 2007; 102: 264-270
        • Chisolm M.S.
        • Tuten M.
        • Brigham E.C.
        • Strain E.C.
        • Jones H.E.
        Relationship between cigarette use and mood/anxiety disorders among pregnant methadone‐maintained patients.
        American Journal of Addictions. 2009; 18: 422-429
        • Choo R.E.
        • Huestis M.A.
        • Schroeder J.R.
        • Shin A.S.
        • Jones H.E.
        Neonatal abstinence syndrome in methadone‐exposed infants is altered by level of prenatal tobacco exposure.
        Drug and Alcohol Dependence. 2004; 75: 253-260
        • Comer V.G.
        • Annitto W.J.
        Buprenorphine: A safe method for detoxifying pregnant heroin addicts and their unborn.
        American Journal on Addictions. 2004; 13: 317-318
        • Connock M.
        • Juarez‐Garcia A.
        • Jowett S.
        • Frew E.
        • Liu Z.
        • Taylor R.J.
        • Taylor R.
        Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation.
        Health Technology Assessment. 2007; 11: 1-171
        • Dashe J.
        • Sheffield J.S.
        • Olscher D.A.
        • Todd S.J.
        • Jackson G.L.
        • Wendel G.D.
        Relationship between maternal methadone dosage and neonatal withdrawal.
        American College of Obstetricians and Gynecologists. 2002; 100: 1244-1249
        • Dawe S.
        • Harnett P.H.
        • Rendalls V.
        • Staiger P.
        Improving family functioning and child outcomes in methadone maintained families: The parents under pressure programme.
        Drug and Alcohol Review. 2003; 22: 299-307
        • Ebner N.
        • Rohmeister K.
        • Winklbaur B.
        • Baewert A.
        • Jagsch R.
        • Peternell A.
        • Fischer G.
        Management of neonatal abstinence syndrome in neonates born to opioid maintained women.
        Drug Alcohol Dependence. 2007; 87: 131-138
        • Fajemirokun‐Odudeyi O.
        • Sinha C.
        • Tutty S.
        • Pairaudeau P.
        • Armstrong D.
        • Phillips T.
        • Lindow S.W.
        Pregnancy outcome in women who use opiates.
        European Journal of Obstetrics & Gynecology and Reproductive Biology. 2005; 126: 170-175
        • Farid W.O.
        • Dunlop S.A.
        • Tait R.J.
        • Hulse G.K.
        The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: Review of human and animal data.
        Current Neuropharmacology. 2008; 6: 125-150
        • Fischer G.
        • Ortner R.
        • Rohrmeister K.
        • Jagsch R.
        • Baewer A.
        • Langer M.
        • Aschauer H.
        Methadone versus buprenorphine in pregnant addicts: A double‐blind, double dummy comparison study.
        Addiction. 2006; 101: 275-281
        • Guthrie S.K.
        • Augustin S.G.
        Psychiatric disorders.
        in: Koda‐Kimble M.A. Young L.Y. Kradjan W.A. Guglielmo B.J. Alldredge B.K. Corelli R.L. Williams B.R. Applied therapeutics: The clinical use of drugs. 9th ed. Wolters Kluwer Lippincott Williams & Wilkins, Philadelphia, PA2008: 76-87
        • Isemann B.
        • Meinzen‐Deer J.
        • Akinbi H.
        Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome.
        Journal of Perinatology. 2011; 31: 25-29
        • Jansson L.M.
        Commentary neonatal abstinence syndrome.
        ActaPaediatric. 2008; 97: 1321-1323
        • Jansson L.M.
        ABM clinical protocol #21: Guidelines for breastfeeding and the drug‐dependent woman. The Academy of Breastfeeding Medicine Protocol Committee.
        Breastfeeding Medicine. 2009; 4: 225-228
        • Jansson L.M.
        • Choo R.E.
        • Harrow C.
        • Velez M.
        • Schroeder J.R.
        • Lowe R.
        • Huestis M.A.
        Concentrations of methadone in breast milk and plasmas in the immediate perinatal period.
        Journal of Human Lactation. 2007; 23: 184-190
        • Jansson L.M.
        • Choo R.
        • Velez M.L.
        • Harrow C.
        • Schroeder J.R.
        • Shakleya D.M.
        • Huestis M.A.
        Methadone maintenance and breastfeeding in the neonatal period.
        Pediatrics. 2008; 121: 106-114
        • Jansson L.M.
        • Choo R.
        • Velez M.L.
        • Lowe R.
        • Huestis M.A.
        Methadone maintenance and long‐term lactation.
        Breastfeeding Medicine. 2008; 3: 34-37
        • Jansson L.M.
        • Dipietro J.A.
        • Velez M.
        • Elko A.
        • Williams E.
        • Milio L.
        • Jones H.E.
        Fetal neurobehavioral effects of exposure to methadone or buprenorphine.
        Neurotoxicology and Teratology. 2011; 33: 240-243
        • Johnson R.E.
        • Jones H.E.
        • Fischer G.
        Use of buprenorphine in pregnancy: Patient management and effects on the neonate.
        Drug and Alcohol Dependence. 2003; 70: S87-S101
        • Jones H.E.
        • Johnson R.E.
        • Jasinski D.R.
        • O'Grady K.E.
        • Chisholm C.
        • Choo R.E.
        • Milio L.
        Buprenorphine versus methadone in the treatment of pregnant opioid‐dependent patients: Effects on the neonatal abstinence syndrome.
        Drug and Alcohol Dependence. 2005; 79: 1-10
        • Jones H.E.
        • Kaltenbach K.
        • Heil S.H.
        • Stine S.
        • Coyle M.
        • Arria A.M.
        • Fischer G.
        Neonatal abstinence syndrome after methadone or buprenorphine exposure.
        New England Journal of Medicine. 2010; 363: 2320-2331
        • Jones H.E.
        • Suess P.
        • Jasinski D.R.
        • Johnson R.E.
        Transferring methadone‐stabilized pregnant patients to buprenorphine using an immediate release morphine transition: An open label exploratory study.
        American Journal on Addiction. 2006; 15: 61-70
        • Kacinko S.L.
        • Jones H.E.
        • Johnson R.E.
        • Choo R.E.
        • Huestis M.A.
        Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.
        Clinical Pharmacology and Therapeutics. 2008; 84: 604-612
        • Kahila H.
        • Saisto T.
        • Kivitie‐Kallio S.
        • Haukkamaa M.
        • Halmesmaki E.
        A prospective study on buprenorphine use during pregnancy: Effects on maternal and neonatal outcome.
        Acta Obstetricia et Gynecologica Scandinavica. 2007; 84: 145-150
        • Kakko J.
        • Heilig M.
        • Sarman I.
        Buprenorphine and methadone treatment of opiate dependence during pregnancy. Comparison of fetal growth and neonatal outcomes in two consecutive case series.
        Drug & Alcohol Dependence. 2008; 96: 69-78
        • Kaltenbach K.
        • Berghella V.
        • Finnegan L.
        Opioid dependence during pregnancy: Effects and management.
        Obstetrics Gynecology Clinics of North America 1998. 1998; 25: 139-151
        • Kayemba‐Kay's S.
        • Laclyde J.P.
        Buprenorphine withdrawal syndrome in newborns: A report of 13 cases.
        Addiction. 2003; 98: 1599-1604
        • Kearnery M.
        Tobacco, alcohol and drug use in childbearing families. Continuing education for registered nurses. March of Dimes Nursing Module.
        March of Dimes Education and Health Promotion, White Plains, NY2008
        • Kuschel C.A.
        • Austerberry L.
        • Cornwell M.
        • Couch R.
        • Rowley R.S.H.
        Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome?.
        Journal of Fetal Neonatology. 2004; 89: 390-393
        • Lejeune C.
        • Simmat‐Durand L.
        • Gourarier L.
        • Aubisson S.
        Prospective multicenter observational study of 260 infants born to 259 opiate‐dependent mothers on methadone or high‐dose buprenorphine substitution.
        Drug and Alcohol Dependence. 2006; 82: 250-257
        • Lim S.
        • Prasad M.
        • Samuels P.
        • Gardner D.
        • Cordero L.
        High‐dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome.
        American Journal of Obstetrics & Gynecology. 2009; 200: 70.e1-70.e5
        • Ludlow J.P.
        • Evans S.F.
        • Hulse G.
        Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse.
        Australian and New Zealand Journal of Obstetrics and Gynaecology. 2004; 44: 302-306
        • McCarthy J.J.
        • Leamon M.H.
        • Parr M.S.
        • Anania B.
        High‐dose methadone maintenance in pregnancy: Maternal and neonatal outcomes.
        American Journal of Obstetrics and Gynecology. 2005; 193: 606-610
        • McGloin J.M.
        • Prate T.C.
        • Piquero A.R.
        A life course analysis of the criminogenic effects of maternal cigarette smoking during pregnancy.
        Journal of Research in Crime and Delinquency. 2006; 43: 412-426
        • Minozzi S.
        • Amato L.
        • Vecchi S.
        • Davoli M.
        Maintenance agonist treatments for opioid dependent pregnant women.
        Cochrane Database Systematic Review. April. 2008; 16: CD006318
        • Nanovskaya T.
        • Deshmukh S.
        • Brooks M.
        • Ahmed M.S.
        Transplacental transfer and metabolism of buprenorphine.
        Journal of Pharmacological Experimental Therapeutics. 2002; 300: 26-33
        • Nanovskaya T.
        • Deshmukh S.
        • Nekhayeva I.
        • Zharikova O.
        • Hankins G.
        • Ahmed S.
        Methadone metabolism by human placenta.
        Biochemical Pharmacology. 2004; 68: 583-591
        • Nanovskaya T.
        • Nekhayeva
        • Karunaratne I.N.
        • Audus K.
        • Hankins G.
        • Ahmed M.
        Role of P‐glycoprotein in transplacental transfer of methadone.
        Biochemical Pharmacology. 2005; 69: 1869-1878
        • Nekhayeva I.
        • Nanovskaya T.
        • Deshmukh S.
        • Zharikova O.
        • Hankins G.
        • Ahmed M.
        Bidirectional transfer of methadone across human placenta.
        Biochemical Pharmacology. 2005; 69: 187-197
        • Nocon J.J.
        Buprenorphine in pregnancy: The advantages.
        Addiction. 2006; 101: 608-609
        • Oei J.
        • Lui K.
        Management of the newborn infant affected by maternal opiates and other drugs of dependency.
        Journal of Paediatrics and Child Health. 2007; 43: 9-18
        • Pizarro D.
        • Habli M.
        • Grier M.
        • Bombrys A.
        • Sibai B.
        • Livingston J.
        Higher maternal doses of methadone does not increase neonatal abstinence syndrome.
        Journal Substance Abuse Treatment. 2011; 40: 295-298
        • Pritham U.
        Effects of breast and formula feedings on neonatal abstinence syndrome.
        Las Vegas, NV2011
        • Rayburn W.F.
        • Bogenschutz M.P.
        Pharmacotherapy for pregnant women with addictions.
        American Journal of Obstetrics and Gynecology. 2004; 191: 1885-1897
        • Sanchez E.S.
        • Bigbee J.W.
        • Fobbs W.
        • Robinson S.E.
        • Sato‐Bigbee C.
        Opioid addition and pregnancy: Perinatal exposure to buprenorphine affects myelination in the developing brain.
        Glia. 2008; 56: 1017-1027
        • Seligman N.S.
        • Salva N.
        • Hayes E.J.
        • Dysart K.C.
        • Pequignot E.C.
        • Baxter J.K.
        Predicting length of treatment for neonatal abstinence syndrome in methadone‐exposed neonates.
        American Journal of Obstetrics & Gynecology. 2008; 199: 396.e1-396.e7
        • Schindler S.D.
        • Eder H.
        • Ortner R.
        • Rohrmeister K.
        • Langer M.
        • Fischer G.
        Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy.
        Addiction. 2003; 98: 103-110
        • Sharp C.
        • Kuschel C.
        Outcomes of infants born to mothers receiving methadone for pain management in pregnancy.
        Archives of Disease in Childhood Fetal Neonatal Education. 2004; 89: 33-36
        • Simmat‐Durand L.
        • Lejeune C.
        • Gourarier L.
        • Groupe d’ Etudes Grossesse et Addictions
        Pregnancy under high‐dose buprenorphine.
        European Journal of Obstetrics, Gynecology and Reproductive Biology. 2009; 142: 119-123
        • Vavrinková B.
        • Binder T.
        Socioeconomic datas, the course of pregnancy and delivery in opioid‐addicted women and women under substitution therapy. Article in Czech; English Abstract.
        Ceska Gynekologie. 2007; 72: 330-335
        • Wouldes T.A.
        • Woodward L.J.
        Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicology Teratology (Epub ahead of print).
        (Retrieved from)